<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385800</url>
  </required_header>
  <id_info>
    <org_study_id>TG002</org_study_id>
    <nct_id>NCT01385800</nct_id>
  </id_info>
  <brief_title>ToleroMune Grass Exposure Unit Study</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled Study to Evaluate Three Doses of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharm-Olam International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Grass pollen allergens are recognised as a major cause of allergic diseases in humans and&#xD;
      animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen&#xD;
      allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass&#xD;
      pollen. ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising&#xD;
      vaccine, currently being developed for the treatment of grass allergy.&#xD;
&#xD;
      This study will look at the efficacy, safety and tolerability of three doses of ToleroMune&#xD;
      Grass in grass allergic subjects following challenge with with grass in an Environmental&#xD;
      Exposure Unit (EEU).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a randomised, double-blind, placebo-controlled, parallel group&#xD;
      study to evaluate the safety and tolerability of ToleroMune Grass in grass allergic subjects&#xD;
      with allergic rhinoconjunctivitis. The efficacy of ToleroMune Grass will be explored in&#xD;
      subjects using an EEU (Environmental Exposure Unit).&#xD;
&#xD;
      The study will consist of 3 study periods. In Period 1, Screening will be performed up to a&#xD;
      maximum of 16 weeks before randomisation and may consist of one or two visits to the clinic,&#xD;
      at the Investigator's discretion. Baseline Challenge will consist of 4 visits to the EEU at&#xD;
      least 3 days before randomisation.&#xD;
&#xD;
      In Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be&#xD;
      randomised to one of four groups and will receive treatment every 2 weeks (Â±2 days) for 14&#xD;
      weeks.&#xD;
&#xD;
      In Period 3, Post Treatment Challenge will consist of 4 visits to the EEU about 25 weeks&#xD;
      after the first administration in the treatment period and assessments will be performed&#xD;
      identical to those at the baseline challenge. Follow-up will be conducted 3-10 days after&#xD;
      PTC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Rhinoconjunctivitis Symptom Score</measure>
    <time_frame>Upto 25 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scores for nasal and non nasal symptoms</measure>
    <time_frame>Upto 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin prick testing</measure>
    <time_frame>Upto 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Nasal Inspiratory Flow</measure>
    <time_frame>Up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grass specific IgA</measure>
    <time_frame>Upto 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grass specific IgE</measure>
    <time_frame>Upto 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grass specific IgG4</measure>
    <time_frame>Up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up tp 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Grass Allergy</condition>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intradermal injection, 1 x 8 administrations 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune Grass Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection 1 x 8 administrations 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune Grass Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection 1 x 8 administrations 2 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ToleroMune Grass Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection 1 x 8 administrations 2 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ToleroMune Grass</intervention_name>
    <description>Intradermal injection 1 x 8 administrations 2 weeks apart</description>
    <arm_group_label>ToleroMune Grass Dose 1</arm_group_label>
    <arm_group_label>ToleroMune Grass Dose 2</arm_group_label>
    <arm_group_label>ToleroMune Grass Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal injection 1 x 8 administrations 2 weeks apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Male or female, aged 18-65 years.&#xD;
&#xD;
          -  Minimum 2-year documented history of rhinoconjunctivitis on exposure to grass.&#xD;
&#xD;
          -  Positive skin prick test to grass allergen.&#xD;
&#xD;
          -  Minimum qualifying rhinoconjunctivitis symptom scores&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  History of asthma.&#xD;
&#xD;
          -  A history of anaphylaxis to grassallergen.&#xD;
&#xD;
          -  Subjects with an FEV1 &lt;80% of predicted.&#xD;
&#xD;
          -  Subjects who cannot tolerate baseline challenge in the EEU.&#xD;
&#xD;
          -  Subjects for whom administration of epinephrine is contra-indicated (e.g. subjects&#xD;
             with acute or chronic symptomatic coronary heart disease or severe hypertension).&#xD;
&#xD;
          -  A history of severe drug allergy, severe angioedema or anaphylactic reaction to food.&#xD;
&#xD;
          -  A history of any significant disease or disorder (e.g. cardiovascular, pulmonary,&#xD;
             gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic,&#xD;
             neoplastic/malignant, psychiatric, major physical impairment).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne K Ellis, MD MSC FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University, Kingston, Ontario</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <last_update_submitted>August 14, 2013</last_update_submitted>
  <last_update_submitted_qc>August 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Grass allergy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Environmental Exposure Unit</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>ToleroMune Grass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

